Table 3.
Multivariate analysis for time to progression in colorectal cancer patients treated with E-FOLFIRI
| Variable | No. (n=49) | Hazard ratio (95% CI) | p-value |
|---|---|---|---|
| Age (yr) | |||
| < 65 | 36 | 1.24 (0.45-3.44) | 0.68 |
| ≥ 65 | 13 | ||
| Sex | |||
| Male | 30 | 1.11 (0.44-2.79) | 0.83 |
| Female | 19 | ||
| Histology | |||
| WD/MD | 43 | 1.89 (0.71-5.08) | 0.21 |
| PD/Mucinous | 6 | ||
| Disease status | |||
| Metastatic | 32 | 1.98 (0.79-4.92) | 0.14 |
| Recurrent | 17 | ||
| Line of treatment | |||
| First line | 22 | 1.07 (0.46-2.49) | 0.88 |
| Second line | 27 | ||
| p16 methylation | |||
| Unmethylated | 35 | 2.97 (1.14-7.74) | 0.027 |
| Methylated | 14 | ||
| CIMP status | |||
| Negative | 32 | 0.58 (0.23-1.45) | 0.24 |
| Positive | 17 | ||
| KRAS mutation | |||
| Wild type | 40 | 3.21 (1.23-8.38) | 0.017 |
| Mutant | 9 | ||
WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; CIMP, CpG island methylator phenotype.